Loading...
XHKG
2196
Market cap9.37bUSD
Oct 09, Last price  
17.87HKD
1D
0.28%
1Q
9.36%
Jan 2017
-24.76%
Name

Shanghai Fosun Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XHKG:2196 chart
P/E
11.94
P/S
0.97
EPS
1.28
Div yield, %
1.96%
Shrs. gr., 5y
0.64%
Rev. gr., 5y
6.49%
Revenues
41.50b
+1.06%
4,082,086,1763,693,301,6783,773,234,2203,850,311,8684,555,421,6866,485,540,8007,340,782,7219,996,409,00812,025,532,04512,608,648,31314,628,820,44218,533,555,41824,918,274,00028,585,152,00030,306,981,00039,011,184,00043,951,547,00041,399,540,00041,067,196,00041,504,097,000
Net income
3.37b
+21.69%
259,157,973625,781,242690,856,5412,498,201,836863,653,9061,165,607,6291,563,916,4441,582,560,3822,112,869,4712,460,093,5872,805,837,0763,124,499,5522,707,923,0003,321,618,0003,662,813,0004,728,711,0003,730,805,0002,386,266,0002,769,887,0003,370,562,000
CFO
6.01b
+34.14%
184,914,259131,477,131233,041,247261,867,525203,362,919316,649,971665,517,0201,011,633,3741,200,214,1911,621,027,8752,110,039,2652,580,225,7752,950,105,2133,222,412,5712,579,774,3493,948,747,0094,217,570,8924,363,275,6344,476,981,2626,005,282,832
Dividend
Jul 16, 20260.45 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumors and hematologic malignancies, as well as immune-inflammatory disorders, metabolism and digestive systems, anti-infection, central nervous system, cardiovascular system, and APIs and intermediates. It also offers mRNA vaccines; medical aesthetic devices, such as medical aesthetic capital equipment, aesthetic dentistry, injectables, and personal care business units; mechanical ventilation devices under the Breas brand; and mobile pre-hospital care; professional in-hospital surgery and covers medical devices; and high-end surgical robots and medical consumables. In addition, the company provides diagnostics solutions comprising biochemical diagnostics, immune diagnostics, molecular diagnostics, microbiological diagnostics, pathological diagnostics, and chronic care management; and healthcare services, specialized medical treatment, online and offline medical services, and insurance services. Further, it engages in the operation of hospitals; and distribution and retail of healthcare products. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Related entities

Subsidiaries
Chindex Hong Kong Limited

Key people

Yuqing Chen
Executive Chairman of the Board · since 2025
Kexin Wang
Executive Co-Chairman of the Board · since 2022
Jing Li
Co-President, Chief Executive Officer - Established Medicines and Manufacturing & Supply Division · since 2025
Xingli Wang
Co-President, Chief Executive Officer - Global R&D Center, Co-Chief Executive Officer - Innovative Medicine Division · since 2025
Wenjie Zhang
Co-President, Co-Chief Executive Officer - Innovative Medicine Division · since 2025
Zhanyu Chen
Chief Financial Officer, Senior Vice President · since 2024
Rongli Feng
Executive President, Chief Human Resources Officer · since 2024
Hang Hu
Senior Vice President · since 2022
Xiang Li
Senior Vice President, Co-President & Chief Scientific Officer - Innovative Pharmaceuticals Division, Co-President - Global R&D Center · since 2025
Donghua Wang
Senior Vice President · since 2025
Xiaoxian Dong
Vice President, Secretary of the Board, Joint Company Secretary · since 2016
Hao Ji
Vice President, General Manager- Anti-Corruption Supervision Department · since 2022
Lilang Lu
Vice President, Co-Chief Executive Officer - Medical Devices Division · since 2023
Lingyuan Meng
Vice President · since 2026
Li Su
Vice President, Executive President - Established Medicines and Manufacturing & Supply Division · since 2022
Fangbing Yuan
Vice President · since 2025
Yue Zhu
Vice President, General Manager - Legal Department · since 2022
Xiaohui Guan
Executive Co-Chairman of the Board · since 2025
President, Chief Executive Officer, Chairman and Chief Executive Officer - Medical Devices Division, Chairman - Medical Diagnosis Division, Executive Director · since 2025
Chief Executive Officer, Executive Director · since 2022
IPO date
Aug 07, 1998
Employees
38,591
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
曹杨路510号9楼
普陀区, SH 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT